Jpmorgan Chase & CO Verona Pharma PLC Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Verona Pharma PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,060 shares of VRNA stock, worth $829,258. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,060
Previous 10,364
35.66%
Holding current value
$829,258
Previous $149,000
171.14%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding VRNA
# of Institutions
174Shares Held
68.7MCall Options Held
704KPut Options Held
685K-
Perceptive Advisors LLC New York, NY6.32MShares$373 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$329 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$295 Million2.01% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx4.22MShares$249 Million2.52% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$209 Million14.95% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.6B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...